Thornberry Nancy 4

What Happened

• Nancy Thornberry, a director of Denali Therapeutics (DNLI), received equity awards on June 3, 2026: 6,408 restricted stock units (RSUs) and a derivative award covering 19,226 shares. Both grants were reported as acquired at $0.00, so no cash was paid. Combined, the awards cover 25,634 underlying shares.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (timely filing).
• Prices: both grants recorded at $0.00 (compensation awards).
• Total shares involved: 6,408 RSUs + 19,226 derivative shares = 25,634 underlying shares.
• Shares owned after transaction: not specified in the filing.
• Footnotes:
  • F1: Each RSU represents a contingent right to one share; vesting tied to schedule below.
  • F2: The 6,408 are unvested RSUs.
  • F3: The derivative award vests 100% upon the earlier of one-year anniversary of grant or the day before the issuer’s next annual meeting.
• Transaction type: Award/Grant (code A) — compensation, not an open-market purchase.

Context

• These awards are compensation grants to a director; they do not indicate an open-market buy or sale. The derivative award appears to be an equity-based grant (option-like or similar) with a one-year cliff vesting, meaning the awards generally vest in full after one year or before the next annual meeting, whichever comes first.